Icon Back Back to Search Results

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

  • Recruiting
  • Diagnostic
  • Interventional
  • Drug
  • PHASE2
  • AdventHealth
  • 18 Years -

Study Purpose

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Intervention

Drug : 18F-rhPSMA-7.3 (Posluma)

Eligibility Requirements

info icon History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.

info icon An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5

info icon Minimum age: 18

info icon Patients who are planned to have an x-ray contrast agent or other PET radiotracer \& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.

info icon Patients currently receiving Androgen Deprivation Therapy (ADT).

Recruiting status

Recruiting

Estimated enrollment

30

 
Study start date

Sep 20, 2024

Study end date

Oct 10, 2027

Last updated

Mar 24, 2025

Primary purpose

Diagnostic

Design

Interventional

Intervention

Drug

Study phase

PHASE2

Allocation

Na

 

Sponsor:

AdventHealth

Collaborator:

Blue Earth Diagnostics

Investigator:

N/A

N/A

Publications

N/A


Websites

N/A

NCT06617481

Clinic Location Investigator Distance RECRUITING STATUS Contact